• Public health concerns should be considered when implementing the TRIPS Agreement. Member States should provide limited exceptions to the patent holder’s exclusive rights in their domestic laws. The issue of compulsory licenses and parallel imports should be allowed.
• Member countries should make the fullest use of the periods of transition for incorporating the necessary provisions into their domestic laws.
• Member countries should undertake necessary measures to monitor the impact of the Agreement on access to essential drugs.
Agreement Rev. 25 July 2000